How were (KITE)'s earnings last quarter?

(KITE) (NASDAQ:KITE) released its quarterly earnings data on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $5.74 million. (KITE)'s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.54) EPS.

What other stocks do shareholders of (KITE) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (KITE) investors own include Puma Biotechnology (PBYI) , (MDVN) (MDVN) , BioMarin Pharmaceutical (BMRN) , Incyte (INCY) , First Solar (FSLR) , Dynavax Technologies (DVAX) , United Airlines (UAL) , Juno Therapeutics (JUNO) , Array Technologies (ARRY) and bluebird bio (BLUE) .

NASDAQ:KITE

(KITE) (KITE) Stock Price, News & Analysis

→ With the “Bitcoin Loophole” you can supercharge the gains by 10x or more (From DTI) (Ad)

Free KITE Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Today's Range: $179.79
▼
$179.79
50-Day Range: N/A
52-Week Range: $39.82
▼
$179.99

Volume: N/A
Average Volume: 1.65 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get (KITE) alerts:

Ad DTI

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

Click here and I’ll give you all the details.

About (KITE) Stock (NASDAQ:KITE)

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Ad DTI

Don’t expose yourself to stocks during the week

Click here and I’ll give you all the details.

KITE Stock News Headlines

April 17, 2024 | msn.com

Ban on kite flying: LHC issues notices to Punjab govt, IGP

April 17, 2024 | msn.com

This week in Kansas City: ‘Ted Lasso’ funnyman at Kauffman Center, plus kite festival

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

April 15, 2024 | msn.com

Austin kite fest flies high at Zilker Park

April 15, 2024 | msn.com

Austin hosts 96th Kite Fest with shopping, food, and other activities

April 14, 2024 | msn.com

Go fly a kite! Thousands turn out for iconic Austin festival

April 14, 2024 | msn.com

Benjamin Franklin's Kite Experiment: Why The French Thought He Invented Electricity

April 13, 2024 | msn.com

Lubbock Kite Flight held at Mackenzie Park to memorialize children killed in Gaza

April 18, 2024 | DTI (Ad)

Don’t expose yourself to stocks during the week

April 13, 2024 | msn.com

CARD postpones Kite Day due to inclement weather

April 12, 2024 | msn.com

Things to do in Denver: Kite festival, wine walk and more

April 11, 2024 | msn.com

Things to do in the Austin area this weekend: Moontower Comedy Festival, ABC Kite Fest and more

April 11, 2024 | msn.com

Kite Surfer in Australia Has Once-In-A-Lifetime Encounter With Stingray

April 11, 2024 | msn.com

Rockport Kite Festival returns for third year Saturday

April 11, 2024 | msn.com

Company develops revolutionary 'underwater kite' that could transform power generation: 'A new agenda for renewable energy'

April 11, 2024 | msn.com

Road closures planned for Longhorn Run, ABC Kite Fest in Austin

April 11, 2024 | finance.yahoo.com

Austin’s ABC Kite Fest Announces Final Plans for April 14th Event

April 10, 2024 | msn.com

23rd annual Blue Ridge Kite Festival ready to take flight

April 10, 2024 | msn.com

Power, mega and stunt: Kite fans will see an impressive array at Lee’s Summit fest

April 10, 2024 | msn.com

2024 ABC Kite Fest to draw thousands to Austin's Zilker Park this weekend

April 9, 2024 | msn.com

Lifeboat rushes to save kite surfer that turns out to be Baby Yoda

April 9, 2024 | msn.com

Crackdown against kite flying continues

April 7, 2024 | msn.com

Annual kite and piñata festival held at Nathanael Greene/Close Memorial Park

April 7, 2024 | msn.com

Springfield Sister Cities Association holds kite and piñata festival

April 7, 2024 | msn.com

Kite surfer stuck in tree, rescued by firefighters

April 6, 2024 | msn.com

Walton County Fire Rescue responded to a kite surfer stuck in a tree

April 6, 2024 | msn.com

Donald Trump makes bizarre claim about Biden's ‘worst’ SOTU address: 'He was higher than a kite'

See More Headlines

Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2017
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: N/A
Industry: N/A
Sub-Industry: N/A
Current Symbol: NASDAQ:KITE
CUSIP: N/A
CIK: 1510580
Web: www.kitepharma.com
Phone: +1-310-8249999
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Arie S. Belldegrun
Executive Chairman of the Board, President, Chief Executive Officer, Founder
Paul L. Jenkinson
Chief Financial Officer
Cynthia M. Butitta
Chief Operating Officer
David Chang M.D. Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer
Helen S. Kim
Executive Vice President - Business Development
Timothy L. Moore
Executive Vice President - Technical Operations
Christine Cassiano
Senior Vice President - Corporate Communications and Investor Relations
Bio & Compensation -
Jian Irish Ph.D.
Senior Vice President - Supply Chain
Bio & Compensation -
Jeffrey Wiezorek M.D.
Senior Vice President - Clinical Development
Shawn Cline Tomasello
Chief Commercial Officer

KITE Stock Analysis - Frequently Asked Questions

How were (KITE)'s earnings last quarter?: (KITE) (NASDAQ:KITE) released its quarterly earnings data on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to the consensus estimate of $5.74 million. (KITE)'s revenue for the quarter was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.54) EPS.
What other stocks do shareholders of (KITE) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other (KITE) investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), Juno Therapeutics (JUNO), Array Technologies (ARRY) and bluebird bio (BLUE).

This page (NASDAQ:KITE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

(KITE) (KITE) Stock Price, News & Analysis

About (KITE) Stock (NASDAQ:KITE)

KITE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

KITE Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info